These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33869738)

  • 1. SQ3370 Activates Cytotoxic Drug via Click Chemistry at Tumor and Elicits Sustained Responses in Injected & Non-injected Lesions.
    Srinivasan S; Yee NA; Wu K; Zakharian M; Mahmoodi A; Royzen M; Oneto JMM
    Adv Ther (Weinh); 2021 Mar; 4(3):. PubMed ID: 33869738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SQ3370, the first clinical click chemistry-activated cancer therapeutic, shows safety in humans and translatability across species.
    Srinivasan S; Yee NA; Zakharian M; Alečković M; Mahmoodi A; Nguyen TH; Mejía Oneto JM
    bioRxiv; 2023 Mar; ():. PubMed ID: 37034617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Click activated protodrugs against cancer increase the therapeutic potential of chemotherapy through local capture and activation.
    Wu K; Yee NA; Srinivasan S; Mahmoodi A; Zakharian M; Mejia Oneto JM; Royzen M
    Chem Sci; 2021 Jan; 12(4):1259-1271. PubMed ID: 34163888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Click Chemistry Selectively Activates an Auristatin Protodrug with either Intratumoral or Systemic Tumor-Targeting Agents.
    McFarland JM; Alečković M; Coricor G; Srinivasan S; Tso M; Lee J; Nguyen TH; Mejía Oneto JM
    ACS Cent Sci; 2023 Jul; 9(7):1400-1408. PubMed ID: 37521794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
    Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
    Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
    Wong HL; Rauth AM; Bendayan R; Wu XY
    Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin uptake in ascitic lymphoma model: resistance or curability is governed by tumor cell density and prolonged drug retention.
    Zaleskis G; Garberytė S; Pavliukevičienė B; Valinčius G; Characiejus D; Mauricas M; Kraśko JA; Žilionytė K; Žvirblė M; Pašukonienė V
    J Cancer; 2020; 11(22):6497-6506. PubMed ID: 33046971
    [No Abstract]   [Full Text] [Related]  

  • 8. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and evaluation of clickable gelatin-oleic nanoparticles using fattigation-platform for cancer therapy.
    Meghani NM; Amin HH; Park C; Park JB; Cui JH; Cao QR; Lee BJ
    Int J Pharm; 2018 Jul; 545(1-2):101-112. PubMed ID: 29698822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Size-adjustable micelles co-loaded with a chemotherapeutic agent and an autophagy inhibitor for enhancing cancer treatment via increased tumor retention.
    Rao J; Mei L; Liu J; Tang X; Yin S; Xia C; Wei J; Wan D; Wang X; Wang Y; Li M; Zhang Z; He Q
    Acta Biomater; 2019 Apr; 89():300-312. PubMed ID: 30878446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.
    Saleh MN; Sugarman S; Murray J; Ostroff JB; Healey D; Jones D; Daniel CR; LeBherz D; Brewer H; Onetto N; LoBuglio AF
    J Clin Oncol; 2000 Jun; 18(11):2282-92. PubMed ID: 10829049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy.
    Kim W; Yoon HY; Lim S; Stayton PS; Kim IS; Kim K; Kwon IC
    J Control Release; 2021 Jan; 329():223-236. PubMed ID: 33290794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of PolyMPC-Dox Prodrugs in a Human Ovarian Tumor Model.
    Wong KE; Mora MC; Skinner M; McRae Page S; Crisi GM; Arenas RB; Schneider SS; Emrick T
    Mol Pharm; 2016 May; 13(5):1679-87. PubMed ID: 27023764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo.
    Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z
    Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin Paradoxically Ameliorates Tumor-Induced Inflammation in Young Mice.
    Abdelgawad IY; Grant MKO; Popescu FE; Largaespada DA; Zordoky BN
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Near-infrared-triggered in situ hybrid hydrogel system for synergistic cancer therapy.
    Zhang H; Zhu X; Ji Y; Jiao X; Chen Q; Hou L; Zhang H; Zhang Z
    J Mater Chem B; 2015 Aug; 3(30):6310-6326. PubMed ID: 32262750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry.
    Zeglis BM; Sevak KK; Reiner T; Mohindra P; Carlin SD; Zanzonico P; Weissleder R; Lewis JS
    J Nucl Med; 2013 Aug; 54(8):1389-96. PubMed ID: 23708196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A folate modified pH sensitive targeted polymeric micelle alleviated systemic toxicity of doxorubicin (DOX) in multi-drug resistant tumor bearing mice.
    Li X; Yang X; Lin Z; Wang D; Mei D; He B; Wang X; Wang X; Zhang Q; Gao W
    Eur J Pharm Sci; 2015 Aug; 76():95-101. PubMed ID: 25917524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor targeting using anti-her2 immunoliposomes.
    Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
    J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.